PHARMACY

Check it out: State Pharmacy Now

BY Rob Eder

This month, the Drug Store News Group introduced State Pharmacy Now, an exciting, new, first-of-its-kind digital magazine and a must-read for pharmacy professionals across the country, that DSN has partnered with the National Alliance of State Pharmacy Associations to produce.

Download your free issue at nxtbook.com/nxtbooks/lebharfriedman/spn_201310/, and let me know what you think. Email me at [email protected].

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?

View Results

Loading ... Loading ...
PHARMACY

J&J buys experimental hepatitis C drug from GSK

BY Alaric DeArment

TITUSVILLE, N.J. — A subsidiary of Johnson & Johnson has acquired rights to an experimental drug for hepatitis C from GlaxoSmithKline.

Janssen Pharmaceuticals announced that it had bought, for an undisclosed among, the drug GSK2336805 from GSK. The drug, which belongs to a class known as NS5a replication complex inhibitors, is currently in mid-stage development.

As part of the deal, Janssen acquires all rights to develop and commercialize the drug, including in combination with other drugs. The drug maker will start phase-2 studies to study its use in combinations with its own experimental drugs, TMC435 (simeprevir) and TMC647055. The company said it would test the GSK drug in combinations that did not include interferons, biotech drugs commonly used to treat hepatitis C.

Janssen recently said that data from a phase-2a study in which simeprevir was combined with another drug, sifosbuvir, was accepted as a late-breaking presentation at the annual meeting of the American Association for the Study of Liver Diseases, which will take place Nov. 1-5 in Washington.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?

View Results

Loading ... Loading ...
PHARMACY

QS/1, RxTran partner on pharmacy translation

BY Alaric DeArment

CAMBRIDGE, Mass. — QS/1 will offer its pharmacy clients prescription-translation software under a new partnership with pharmacy language service firm RxTran, the two companies said Thursday.

RxTran is delivered as a software-as-a-service application, allowing pharmacies to quickly and accurately provide written prescription translations to customers with limited English proficiency, thus providing them with a fuller understanding of medication directions and usage. According to the U.S. Census Bereau, the population of people with limited English proficiency grew by 80% between 1990 and 2010.

"QS/1 is committed to providing its pharmacy customers with the tools they need to offer the best patient care possible," QS/1 senior manager for marketing and analyst Michael Ziegler said. "Using RxTran allows pharmacies to translate prescription information into a patient’s native language."

RxTran provides translation services in Arabic, Bengali, French, German, Greek, Haitian Creole, Hindi, Italian, Korean, Portuguese, Russian, simplified and traditional Chinese character sets, Spanish, Tagalog and Vietnamese.

"We are excited and proud to partner with QS/1," RxTran CEO Brian Kratt said. "The integration of these technologies provides pharmacies with an affordable language solution that enables them to improve patient safety and provide better patient care to limited-English-proficiency customers."

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?

View Results

Loading ... Loading ...